Breaking News Instant updates and real-time market news.

AMGN

Amgen

$174.63

0.9 (0.52%)

, NVS

Novartis

$77.15

-0.45 (-0.58%)

19:08
05/17/18
05/17
19:08
05/17/18
19:08

Amgen's Aimovig priced at $575 per month or $6,900 annually

Amgen further states: "Amgen (AMGN) and Novartis (NVS) are committed to supporting the migraine community and to helping appropriate patients with affordable access to Aimovig. The Aimovig Ally product support program has been created to help patients navigate insurance coverage and identify potential access resources for those who are uninsured or underinsured. The U.S. list price of Aimovig is $575 for once monthly 70 or 140 mg single-use prefilled SureClick autoinjector, or $6,900 annually. The price of Aimovig reflects the value it brings to patients and society, including the financial impact on sufferers, caregivers and employers, while also factoring in critical issues such as patient affordability, and fair and timely access. While out-of-pocket costs will vary depending on insurance status, the Aimovig Copay Program may be able to help reduce a patient's out-of-pocket costs to as little as $5 per month for eligible patients with commercial insurance."

AMGN

Amgen

$174.63

0.9 (0.52%)

NVS

Novartis

$77.15

-0.45 (-0.58%)

  • 17

    May

  • 21

    May

  • 22

    May

  • 28

    May

  • 05

    Jun

AMGN Amgen
$174.63

0.9 (0.52%)

04/25/18
RBCM
04/25/18
NO CHANGE
Target $183
RBCM
Sector Perform
Amgen price target lowered to $183 from $189 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $183 and kept his Sector Perform rating after the company's Q1 results. The analyst notes that despite the earnings beat and higher FY18 midpoint guidance, he is more cautious as Amgen's base products drove the revenue gains. MacKay adds that he remains concerned by the competitive threats to Amgen's legacy business.
04/25/18
COWN
04/25/18
NO CHANGE
Target $204
COWN
Outperform
Amgen shares remain undervalued, says Cowen
Cowen analyst Eric Schmidt noted Amgen reported better than expected Q1 results and tweaked the lower end of its revenue guidance. The analyst said the guidance appears conservative in light of sales trends. Schmidt reiterated his Outperform rating and $204 price target on Amgen, noting he believes the shares remain undervalued.
05/15/18
MZHO
05/15/18
NO CHANGE
Target $200
MZHO
Buy
Amgen buyback activity could buoy shares, says Mizuho
Mizuho analyst Salim Syed says that for Amgen to buy back the $2B-$4B of its own stock this quarter, as it said it would do, it would have to make up 5%-11% of daily volume traded every day in the current quarter. The analyst is "not fully convinced this math has been entirely digested by the Street." This could potentially act as a buoy for the stock this quarter, Syed tells investors in a research note. The analyst keeps a Buy rating on the shares with a $200 price target.
05/16/18
MSCO
05/16/18
NO CHANGE
Target $200
MSCO
Overweight
Epogen biosimilar should have little impact on Amgen, says Morgan Stanley
After the FDA approved Retacrit, Pfizer's (PFE) biosimilar version of Amgen's (AMGN) Epogen, Morgan Stanley analyst Matthew Harrison said he does not see significant impact to his forecasts due to the news, noting that Amgen has already discounted Epogen net selling price significantly to secure an extended supply agreement with DaVita (DVA). Amgen renegotiated the supply agreement in early 2017 and the vast majority of Epogen volume is from DaVita, added Harrison, who maintains an Overweight rating and $200 price target on Amgen shares.
NVS Novartis
$77.15

-0.45 (-0.58%)

04/18/18
BERN
04/18/18
NO CHANGE
BERN
Spark Therapeutics, uniQure may be potential takeout targets, says Bernstein
Following AveXis (AVXS) acquisition by Novartis (NVS), Bernstein analyst Vincent Chen says the potential next target should have a strong portfolio fit and innovation-oriented scientifically-minded management teams likely comfortable with the technology platform. For acquisition targets, the analyst sees two flavors, namely late stage more de-risked gene therapy companies, for which Spark (ONCE) comes to mind, and less costly but riskier earlier-stage platforms, for which uniQure (QURE), Voyager (VYGR) and REGENXBIO (RGNX) come to mind.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Wells says bottom has not been reached in generics pricing
After Aceto (ACET) cited the continued intense competitive and pricing pressures in the generic industry when withdrawing its guidance last night, and Novartis (NVS) this morning reported that net sales at its generic unit Sandoz dropped 4% in the quarter, Wells Fargo analyst Davis Maris says he's not ready to call the bottom in generics pricing. Those that have are premature, Maris tells investors in a research note titled "Negative Read Throughs For Generics Continue." The Aceto and Sandoz pricing news shows the data continue to be negative for U.S. generic industry pricing, the analyst contends. He sees a negative read-through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL).
04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.
05/01/18
RBCM
05/01/18
NO CHANGE
RBCM
Sector Perform
Regeneron's Eylea faces strong competition from brolucizumab, says RBC Capital
RBC Capital analyst Kennen MacKay says yesterday's phase 3 presentation of data from Novartis (NVS) regarding the prospects of brolucizumab in wet age-related macular degeneration suggests that the treatment is strongly positioned vs. Regeneron's (REGN) Eylea. MacKay adds that Novartis intends to submit the Biologics License Applications for brolucizumab in December of this year, with expected launch in the second half of 2019. The analyst keeps his Sector Perform rating on Regeneron.

TODAY'S FREE FLY STORIES

LOW

Lowe's

$85.74

-1.63 (-1.87%)

09:05
05/23/18
05/23
09:05
05/23/18
09:05
Hot Stocks
Breaking Hot Stocks news story on Lowe's »

Lowe's outgoing CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

LOW

Lowe's

$85.74

-1.63 (-1.87%)

, JCP

J.C. Penney

$2.33

-0.175 (-6.99%)

09:05
05/23/18
05/23
09:05
05/23/18
09:05
Hot Stocks
Outgoing Lowe's CEO says Ellison the 'ideal' person to serve as next CEO »

Retiring Chairman and CEO…

LOW

Lowe's

$85.74

-1.63 (-1.87%)

JCP

J.C. Penney

$2.33

-0.175 (-6.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.57

-0.69 (-0.25%)

09:04
05/23/18
05/23
09:04
05/23/18
09:04
Technical Analysis
Technical Take: SPDR S&P 500 ETF falls heading toward the open »

At time of writing the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.57

-0.69 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLNS

Colony NorthStar

$5.78

-0.09 (-1.53%)

09:04
05/23/18
05/23
09:04
05/23/18
09:04
Hot Stocks
Colony NorthStar announces additional $300M stock repurchase program »

Colony NorthStar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

RMTI

Rockwell Medical

$5.94

-0.06 (-1.00%)

09:04
05/23/18
05/23
09:04
05/23/18
09:04
Hot Stocks
Rockwell Medical board removes CFO after 'unauthorized' filing »

Rockwell Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$50.87

-1.4 (-2.68%)

, CAA

CalAtlantic

$0.00

(0.00%)

09:04
05/23/18
05/23
09:04
05/23/18
09:04
Recommendations
Lennar, CalAtlantic analyst commentary  »

Lennar price target…

LEN

Lennar

$50.87

-1.4 (-2.68%)

CAA

CalAtlantic

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

H

Hyatt

$80.47

-0.725 (-0.89%)

09:03
05/23/18
05/23
09:03
05/23/18
09:03
Hot Stocks
Hyatt opens Regency Shenzhen Airport Hotel »

Hyatt announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$61.40

-0.71 (-1.14%)

09:02
05/23/18
05/23
09:02
05/23/18
09:02
Hot Stocks
Abbott receives FDA approval for XIENCE Sierra »

Abbott announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBL

Jabil Circuit

$28.27

0.11 (0.39%)

09:02
05/23/18
05/23
09:02
05/23/18
09:02
Hot Stocks
Jabil expands in Israel with opening of Optics Technology Innovation Center »

Green Point, a division…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNC

SS&C

$49.52

-0.47 (-0.94%)

, CBSH

Commerce Bancshares

$65.50

0.11 (0.17%)

09:01
05/23/18
05/23
09:01
05/23/18
09:01
Hot Stocks
Commerce Bancshares picks SS&C for CECL transition »

SS&C Technologies…

SSNC

SS&C

$49.52

-0.47 (-0.94%)

CBSH

Commerce Bancshares

$65.50

0.11 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 12

    Jun

AVID

Avid Technology

$5.00

-0.02 (-0.40%)

09:01
05/23/18
05/23
09:01
05/23/18
09:01
Hot Stocks
Avid Technology selected by Seneca College for media facilities upgrade »

Avid announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFC

VF Corp.

$80.43

-0.48 (-0.59%)

09:00
05/23/18
05/23
09:00
05/23/18
09:00
Recommendations
VF Corp. analyst commentary  »

VF Corp. removed as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$6.91

-0.05 (-0.72%)

08:59
05/23/18
05/23
08:59
05/23/18
08:59
Syndicate
Pfenex 6.8M share Spot Secondary priced at $5.50 »

Barclays and William…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

TIF

Tiffany

$102.26

-0.96 (-0.93%)

08:58
05/23/18
05/23
08:58
05/23/18
08:58
Hot Stocks
Tiffany says engagement category is at the core of the company »

Says paper flower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 26

    Jun

IGT

International Game

$28.47

-1.28 (-4.30%)

08:56
05/23/18
05/23
08:56
05/23/18
08:56
Syndicate
International Game 18M share Secondary priced at $28.25 »

Credit Suisse acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 23

    May

TSC

TriState Capital

$27.05

0.2 (0.74%)

08:56
05/23/18
05/23
08:56
05/23/18
08:56
Syndicate
TriState Capital 2.2M share Spot Secondary priced at $25.90 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 23

    May

TJX

TJX

$87.50

2.84 (3.35%)

, M

Macy's

$33.12

-1.48 (-4.28%)

08:55
05/23/18
05/23
08:55
05/23/18
08:55
Recommendations
TJX, Macy's, Kohl's, J.C. Penney analyst commentary  »

TJX results 'more…

TJX

TJX

$87.50

2.84 (3.35%)

M

Macy's

$33.12

-1.48 (-4.28%)

KSS

Kohl's

$60.60

-4.87 (-7.44%)

JCP

J.C. Penney

$2.33

-0.175 (-6.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

MU

Micron

$58.95

3.47 (6.25%)

, BAC

Bank of America

$30.89

0.34 (1.11%)

08:55
05/23/18
05/23
08:55
05/23/18
08:55
Options
Notable open interest changes for May 23rd »

Tuesday's total…

MU

Micron

$58.95

3.47 (6.25%)

BAC

Bank of America

$30.89

0.34 (1.11%)

NXPI

NXP Semiconductors

$115.55

0.84 (0.73%)

CHK

Chesapeake

$4.54

-0.065 (-1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

SLB

Schlumberger

$73.74

-1.28 (-1.71%)

, EOG

EOG Resources

$123.76

-3.69 (-2.90%)

08:55
05/23/18
05/23
08:55
05/23/18
08:55
Conference/Events
UBS to hold a conference »

Global Oil & Gas…

SLB

Schlumberger

$73.74

-1.28 (-1.71%)

EOG

EOG Resources

$123.76

-3.69 (-2.90%)

HP

Helmerich & Payne

$70.74

-1.83 (-2.52%)

RRC

Range Resources

$15.45

-0.63 (-3.92%)

SWN

Southwestern Energy

$4.66

-0.07 (-1.48%)

TDW

Tidewater

$31.48

0.1 (0.32%)

NE

Noble Corp.

$5.86

-0.15 (-2.50%)

HES

Hess Corp.

$63.83

-1.42 (-2.18%)

TUSK

Mammoth Energy

$34.59

-1.27 (-3.54%)

DVN

Devon Energy

$41.82

-0.51 (-1.20%)

ICD

Independence Contract Drilling

$4.89

-0.25 (-4.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 30

    May

  • 25

    Jun

  • 27

    Jun

  • 20

    Jul

  • 19

    Aug

TMO

Thermo Fisher

$217.88

1.2 (0.55%)

08:55
05/23/18
05/23
08:55
05/23/18
08:55
Conference/Events
Thermo Fisher to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

CY

Cypress Semiconductor

$16.31

0.2 (1.24%)

08:54
05/23/18
05/23
08:54
05/23/18
08:54
Initiation
Cypress Semiconductor initiated  »

Cypress Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 13

    Jun

  • 14

    Jun

TOL

Toll Brothers

$39.46

-4.14 (-9.50%)

08:52
05/23/18
05/23
08:52
05/23/18
08:52
Recommendations
Toll Brothers analyst commentary  »

Toll Brothers price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

$21.92

0.5 (2.33%)

08:51
05/23/18
05/23
08:51
05/23/18
08:51
Recommendations
Marvell analyst commentary  »

Marvell April quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

IDTI

Integrated Device

$32.49

0.41 (1.28%)

08:50
05/23/18
05/23
08:50
05/23/18
08:50
Initiation
Integrated Device initiated  »

Integrated Device…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

TIF

Tiffany

$102.26

-0.96 (-0.93%)

08:49
05/23/18
05/23
08:49
05/23/18
08:49
Hot Stocks
Tiffany says it had success in Japan, Europe »

Says sales rose 18% in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.